| Literature DB >> 28628457 |
Sylvain A Lother, Walter Demczuk, Irene Martin, Michael Mulvey, Brenden Dufault, Philippe Lagacé-Wiens, Yoav Keynan.
Abstract
The incidence of group C and G Streptococcus (GCGS) bacteremia, which is associated with severe disease and death, is increasing. We characterized clinical features, outcomes, and genetic determinants of GCGS bacteremia for 89 patients in Winnipeg, Manitoba, Canada, who had GCGS bacteremia during 2012-2014. Of the 89 patients, 51% had bacteremia from skin and soft tissue, 70% had severe disease features, and 20% died. Whole-genome sequencing analysis was performed on isolates derived from 89 blood samples and 33 respiratory sample controls: 5 closely related genetic lineages were identified as being more likely to cause invasive disease than non-clade isolates (83% vs. 57%, p = 0.002). Virulence factors cbp, fbp, speG, sicG, gfbA, and bca clustered clonally into these clades. A clonal distribution of virulence factors may account for severe and fatal cases of bacteremia caused by invasive GCGS.Entities:
Keywords: Canada; Streptococcus dysgalactiae; bacteremia; bacteria; genome sequencing; group C Streptococcus; group G Streptococcus; invasive disease; virulence factor
Mesh:
Substances:
Year: 2017 PMID: 28628457 PMCID: PMC5512470 DOI: 10.3201/eid2307.161259
Source DB: PubMed Journal: Emerg Infect Dis ISSN: 1080-6040 Impact factor: 6.883
Demographic and other variables among patients with group C and G Streptococcus bacteremia causing severe infections, Winnipeg, Manitoba, Canada, 2012–2014*
| Patient variable | Value |
|---|---|
| Demographic characteristic | |
| Median age, y ± SD | 61 ± 18.4 (0–99) |
| Age groups, y | |
| <18 | 1/89 (1) |
| 18–64 | 52/89 (58) |
|
| 36/89 (40) |
| Sex | |
| M | 56/89 (63) |
| F | 33/89 (37) |
| Medical history† | |
| Active alcohol abuse | 12/88 (14) |
| Active malignancy | 16/88 (18) |
| Active smoker | 17/88 (19) |
| Asthma or COPD | 12/88 (14) |
| Cardiovascular disease | 41/88 (47) |
| Chronic kidney disease | 25/88 (28) |
| Diabetes mellitus | 38/88 (43) |
| Dialysis dependent | 10/88 (11) |
| History of intravenous drug use | 3/88 (3) |
| Immunosuppressive drug use | 11/88 (13) |
| Total parental nutrition | 3/88 (3) |
| No predisposing conditions | 8/88 (9) |
| Clinical source of bacteremia‡ | |
| Skin and soft tissue infection | 43/84 (51) |
| Intraabdominal or gastrointestinal infection | 3/84 (4) |
| Pharyngitis | 0/84 |
| Osteomyelitis and discitis | 1/84 (1) |
| Meningitis | 1/84 (1) |
| Septic arthritis | 2/84 (2) |
| Infectious endocarditis | 6/84 (7) |
| Primary bacteremia without source | 31/84 (37) |
| Clinical characteristic§ | |
| Temperature | 48/83 (58) |
| Mean arterial pressure | 50/82 (61) |
| Heart rate | 63/83 (76) |
| Glasgow Coma Scale <15 | 36/84 (43) |
*Values are no. patients in category/total no. patients with data available (%) except as indicated. COPD, chronic obstructive pulmonary disease. †Data missing for 1 patient. ‡Data missing for 5 patients. Data missing or partially missing for 7 patients.
Death and markers of disease severity among patients with group C and G Streptococcus bacteremia causing severe infections, Winnipeg, Manitoba, Canada, 2012–2014*
| Disease severity marker | Value |
|---|---|
| Death | 18/89 (20) |
| Severe disease | 62/89 (70) |
| Streptococcal toxic shock syndrome† | 14/82 (17) |
| Rapid Emergency Medicine Score | 29/82 (35) |
| High risk Simple Clinical Score | 50/82 (61) |
| Vasopressor support required† | 16/84 (19) |
| Ventilatory support required† | 14/84 (17) |
| Admission to intensive care unit required† | 22/84 (26) |
*Values are no. patients in category/total no. patients with data available (%) except as indicated. †Data missing or partially missing for 5–7 patients. A Rapid Emergency Medicine Score >10 and Simple Clinical Score >8 is considered high risk and associated with a 9.0%–10.3% risk of death.
Figure 1Maximum-likelihood whole-genome, core single-nucleotide variation (SNV) phylogenetic tree of 89 Streptococcus dysgalactiae subsp. equisimilis isolates from the blood of patients with group C and G Streptococcus causing severe infections, Winnipeg, Manitoba, Canada, 2012–2014. Multilocus sequence typing clonal complex relatedness groups were determined by using goeBURST (global optimal eBurst; http://www.phyloviz.net). In the mortality column, red and white squares indicate patient death and survival, respectively. In the severity column, red and white squares represent manifestation of severe and nonsevere disease, respectively. Black and white squares indicate the presence and absence of virulence factor genes, respectively. Scale bar indicates estimated evolutionary divergence between isolates, based on the average genetic distance between strains (estimated substitutions in sample/total high-quality SNVs). ICU, intensive care unit; IE, infectious endocarditis; MLST, multilocus sequence type; STSS, streptococcal toxic shock syndrome; SG, serogroup; ST, MLST; Y, year; M, mortality; S, severity; 1, cbp; 2, fbp; 3, speG; 4, sicG; 5, gfbA; 6, bca.
Figure 2Minimum spanning tree representing the genetic relatedness of multilocus sequence types (MLSTs) of Streptococcus dysgalactiae subsp. equisimilis isolates from patients with group C and G Streptococcus causing severe infections, Winnipeg, Manitoba, Canada, 2012–2014. Genetic relatedness was determined by full goeBURST (global optimal eBurst; http://www.phyloviz.net) analysis using Streptococcus dysgalactiae MLST allelic profiles of 7 housekeeping genes. Numbers on nodes correspond to individual sequence types (STs) and colored nodes correspond to clonal cluster relatedness groups defined by a single-locus variation from a founding ST. Number labels on branches indicate the number of allelic variations between STs; branch lengths are not to scale.
Figure 3Prevalence of sequence types, as characterized by multilocus sequence typing, among blood and respiratory isolates of Streptococcus dysgalactiae subsp. equisimilis from patients with group C and G Streptococcus causing severe infections, Winnipeg, Manitoba, Canada, 2012–2014.
Distribution of virulence factor genes in blood and respiratory isolates of Streptococcus dysgalactiae subsp. equisimilis from patients with group C and G Streptococcus bacteremia causing severe infections, Winnipeg, Manitoba, Canada, 2012–2014
| Gene | Gene product | No. isolates positive for virulence factor/no. tested (%) | Reference | ||
|---|---|---|---|---|---|
| Total isolates | Blood isolate | Respiratory isolate | |||
| Adhesins | |||||
|
| Glyceraldehyde 3-P dehydrogenase | 122/122 (100) | 89/89 (100) | 33/33 (100) | ( |
|
| Laminin-binding surface protein | 122/122 (100) | 89/89 (100) | 33/33 (100) | ( |
|
| Fibronectin-binding protein | 120/122 (98.4) | 89/89 (100) | 31/33 (94) | ( |
|
| Fibronectin-binding protein | 120/122 (98.4) | 89/89 (100) | 31/33 (94) | ( |
|
| Collagen-binding protein | 34/122 (27.9) | 29/89 (33) | 5/33 (15) | ( |
|
| Fibronectin-binding protein | 32/122 (26.2) | 24/89 (30) | 8/33 (24) | ( |
|
| Fibronectin-binding protein | 11/122 (9.0) | 10/89 (11) | 1/33 (3) | ( |
|
| Fibrinogen-binding protein | 0/122 | 0/89 | 0/33 | ( |
|
| Adherence and virulence protein A | 0/122 | 0/89 | 0/33 | ( |
|
| Fibronectin-binding protein | 0/122 | 0/89 | 0/33 | ( |
| Antiphagocytosis | |||||
|
| C protein β antigen | 0/122 | 0/89 | 0/33 | ( |
| Complement protease | |||||
|
| C5a peptidase | 122/122 (100) | 89/89 (100) | 33/33 (100) | ( |
|
| C5a peptidase | 122/122 (100) | 89/89 (100) | 33/33 (100) | ( |
| Exoenzyme | |||||
|
| Hyaluronidase | 122/122 (100) | 89/89 (100) | 33/33 (100) | ( |
| Invasion | |||||
|
| C protein α antigen | 11/122 (9.0) | 5/89 (6) | 6/33 (18) | ( |
| Streptokinases | |||||
|
| Streptokinase | 122/122 (100) | 89/89 (100) | 33/33 (100) | ( |
|
| Streptokinase | 122/122 (100) | 89/89 (100) | 33/33 (100) | ( |
|
| Streptokinase | 122/122 (100) | 89/89 (100) | 33/33 (100) | ( |
| Toxins | |||||
|
| Streptolysin S | 122/122 (100) | 89/89 (100) | 33/33 (100) | ( |
|
| Streptolysin O | 122/122 (100) | 89/89 (100) | 33/33 (100) | ( |
|
| Streptococcus pyrogenic exotoxin G | 81/122 (66.4) | 58/89 (65) | 23/33 (70) | ( |
|
| β hemolysin/cytolysin | 0/122 | 0/89 | 0/33 | ( |
|
| CAMP factor | 0/122 | 0/89 | 0/33 | ( |
| Other | |||||
|
| Streptococcal inhibitor of a complement | 47/122 (38.5) | 35/89 (39) | 12/33 (36) | ( |